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Background: Following above-knee (AK) great saphenous vein (GSV) endovenous laser ablation (EVLA) 40% to 50%
patients have residual varicosities. This randomized controlled trial (RCT) assesses whether more extensive GSV ablation
enhances their resolution and influences symptom improvement.
Method: Sixty-eight limbs (65 patients) with varicosities and above and below-kneeGSV refluxwere randomized toGroup
A: AK-EVLA (n  23); Group B: EVLA mid-calf to groin (n  23); and Group C: AK-EVLA, concomitant below-knee
GSV foam sclerotherapy (n  22). Primary outcomes were residual varicosities requiring sclerotherapy (6 weeks),
improvement in Aberdeen varicose vein severity scores (AVVSS, 12 weeks), patient satisfaction, and complication rates.
Results: EVLA ablated the treated GSV in all limbs. Sclerotherapy requirements were Group A: 14/23 (61%); Group B:
4/23 (17%); and Group C: 8/22 (36%); 2  9.3 (2 df) P  .01 with PA-B  0.006; PB-C  0.19; PA-C  0.14. AVVSS
scores improved in all groups as follows: A: 14.8 (9.3-22.6) to 6.4 (3.2-9.1), (P < .001); B: 15.8 (10.2-24.5) to 2.5
(1.1-3.7), (P < .001); and C: 15.1 (9.0-23.1) to 4.1 (2.3-6.8), (P < .001) and PA-B  0.011, PA -C  0.042. Patient
satisfaction was highest in Group B. BK-EVLA was not associated with saphenous nerve injury.
Conclusions: Extended EVLA is safe, increases spontaneous resolution of varicosities, and has a greater impact on symptom
reduction. Similar benefits occurred after concomitant BK-GSV foam sclerotherapy. (J Vasc Surg 2008;48:173-8.)Minimally invasive ablation techniques are increasingly
used to treat varicose veins, which are most commonly
(70%) the result of sapheno-femoral and great saphenous
vein (GSV) incompetence.1 Endovenous laser ablation
(EVLA) relies on thermal injury to promote occlusion of
the vein and is successful in 88% to 100%2 of limbs. In the
original description of the technique, the GSV was ablated
from the knee to the groin3 without treatment of the
below-knee great saphenous vein (BK-GSV) regardless of
its reflux status. Although concomitant phlebectomy is
advised by some authors,4 others favor deferred treatment
of residual varicosities (phlebectomy5 or foam sclerother-
apy) once they have had the opportunity to shrink follow-
ing abolition of superficial venous reflux. In a previous
study, we found that 44% patients required treatment for
residual varicosities, and this seemed to bemore likely when
there was persistent reflux in the BK-GSV.6 This random-
ized controlled trial compares the efficacy of two different
techniques for correcting both above and below-knee GSV
reflux against the standard above-knee EVLA technique.
The hypothesis was that ablation of a longer segment of
incompetent GSV would reduce the requirement for treat-
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additional symptom improvement.
METHODS
The study was approved by our institutional ethics
committee and was registered as a Current Controlled Trial
(ISRCTN 31316759). It was conducted between October
2005 and June 2007 in a single center. Patients with
below-knee varicosities associated with both above and
below-knee GSV reflux were invited to participate provided
that they wished to undergo EVLA and were suitable for
the technique.6 Patients were excluded from the study if
they had recurrent varicose veins, concomitant reflux in
another axial vein or perforator incompetence, allergy to
sodium tetradecyl sulphate (STD), BK-GSV tortuosity pre-
cluding EVLA, a competent BK-GSV, age 18 years, and
did not give informed consent. Participants were recruited
from 114 consecutive patients with varicose veins due to
isolated sapheno-femoral and GSV reflux. They were ran-
domized to one of three treatment groups (Fig).
Treatment
Group A underwent standard above-knee GSV (AK-
GSV) EVLA and in group B, EVLA was used to ablate the
incompetent GSV from midcalf to groin. Patients in group
C received above-knee EVLA with concomitant catheter-
delivered foam sclerotherapy for their BK-GSV reflux. No
patients were given synchronous sclerotherapy to their
superficial varicosities at the time of EVLA. As EVLA was
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tion, DVT prophylaxis was not used.
Group A: standard above-knee EVLA. The GSV
was cannulated at or just above (5 cm) the knee joint and
a 5F (1.67 mm) endovenous catheter (ELVeS Plus Kath-
eter; Biolitec Group, Bonn, Germany) was passed over a
guidewire. The catheter tip was positioned 1 cm distal to
the sapheno-femoral junction (SFJ). Following infiltration
of tumescent anesthesia (0.1% lignocaine) a 220 m bare
tipped laser fiber (ELVeS Plus Biolitec) was used to deliver
810 nm diode pulsed laser energy (12 W power) at an
energy density of 60 to 70 J/cm. The efficacy of this
protocol has been documented previously.7 A compression
bandage was applied from foot to groin with a length of
foam sponge placed over the treated vein to augment
compression over the GSV. The bandage remained in situ
for 1 week and a compression stocking (23 to 32 mm Hg)
was worn for a further week.
Group B: above and below-knee EVLA. The tech-
nique was identical to that for group A except that the GSV
was cannulated in the calf, either below the lowest incom-
Fig. Details of randomization and randomized controlled trial
(RCT) protocol.petent tributary or 70 cm from the sapheno-femoral junc-tion if GSV reflux persisted beyond this point (catheter
length 70 cm). Laser energy was again delivered at 60 to 70
J/cm.
Group C: AK-GSV EVLA and concomitant BK-
GSV foam sclerotherapy. The GSV was cannulated as in
group B and positioned 1 cm distal to the SFJ. Tumescent
anesthesia was infiltrated only from the knee upwards and
EVLA performed from groin to knee. The laser fiber was
then removed and the catheter gradually pulled back to-
wards the cannulation site in the calf whilst administering
2.5 to 3 ml of 1% STD foam (Fibrovein, STD Pharmaceu-
tical Products Ltd, Hereford, UK) to the below-knee GSV.
The foam was prepared according to the Tessari method.7
A compression bandage was again applied. Group C was
included in the study to assess the combined effect of
AK-EVLA and BK-GSV sclerotherapy as this technique
would be appropriate in patients in whom BK-GSV tortu-
osity precludes laser ablation. This technique might also
provide optimum treatment if group B patients report
excessive rates of saphenous nerve injury.
Data collection and follow-up
Pretreatment clinical severity was assessed using CEAP
grading8 and Aberdeen varicose vein severity scores (AV-
VSS).9 The GSV diameters in midthigh and midcalf were
recorded whilst standing as were the length of vein treated,
laser energy details, and the time taken to complete the
procedure (skin preparation to off-table time). Following
treatment, patients completed a visual analogue scale (1-
100) to assess pain, daily for 1 week and were reviewed at 1,
6, and 12 weeks. At each visit, the study limbs were assessed
clinically and by duplex ultrasound (DUS) to ascertain the
reflux status (significant reflux1 s measured by spectral
trace analysis) of the SFJ and both the AK- and BK-GSV.
Absence of flow in a noncompressible vein represented
successful ablation. GSV diameters were recorded at each
visit.
At 6 weeks, patients were assessed for the presence of
residual varicose veins (visible, palpable superficial varicos-
ities 3 mm diameter) and varicosities associated with
BK-GSV reflux were treated by foam sclerotherapy of this
vein. For isolated varicosities without axial vein reflux, foam
sclerotherapy was administered to the varicosities them-
selves. Sclerotherapy was not performed for BK-GSV reflux
(ultrasound) in the absence of visible varicosities. The
AVVSS was repeated at the 6-week visit.
At 12 weeks, limbs were again assessed for the presence
of residual varicosities. Ablation or patency of the treated
axial vein was confirmed by DUS and patient satisfaction
with treatment determined using a visual analogue scale
(1-100). A log of complications was maintained through-
out the study, and all data were collected and recorded
prospectively. Patients were specifically questioned about
neurological symptoms which were objectively assessed if
present.
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The primary end-points were the presence of residual
varicosities requiring sclerotherapy and an improvement in
the Aberdeen varicose vein symptom severity score (AV-
VSS), a disease specific quality of life measure. The second-
ary end-points were pain scores, patient satisfaction, and
complication rates.
Statistical analysis
The sclerotherapy requirement for each group was
compared using a 2 test. AVVSS improvement within a
group was tested using the Wilcoxon test and compared
between groups by aMann-WhitneyU test. Pain scores and
patient satisfaction were compared using a Student t test
(unpaired) and a 2 test employed to compare complication
rates between the groups. A P value of  .05 was consid-
ered significant. Data are presented as medians (inter-
quartile range) unless stated otherwise. All analyses were
performed with the statistical package SPSS for Windows
(SPSS 14, Chicago, Ill).
RESULTS
Demographic details are given in Table I and treatment
details in Table II. At both 1 and 6 weeks, DUS showed no
retrograde SFJ flow and no groin tributary reflux in any
patient. The AK-GSV was ablated (noncompressible, no
flow) in all limbs of all three groups. In group A, the
Table I. Patient demography and disease severity scores (C
Group A
Age (range) y 40 (30-69)
Male 9
Female 13
Total number of limbs 23 (22 patients)
C2 16
C3 3
C4 3
C5 1
C6 0
CEAP, Clinical, etiology, anatomy, pathology.
Table II. Treatment details
Groups A B C
Length of vein treated
by EVLA (cm)
31 (29-34) 52 (49-60) 30 (28-33)
Length of vein treated
by catheter guided
foam sclerotherapy
at primary
treatment
Nil Nil 19 (17-22)
Laser energy density
(J/cm)
64 (60-71) 61 (59-70) 62 (58-71)
Duration of the
procedure (min)
39 (32-47) 45 (40-56) 44 (40-56)
EVLA, Endovenous laser ablation.BK-GSV remained patent in all instances and 15/23 (65%)showed persistent reflux (1s) at 1 week. Examination at 6
weeks confirmed that reflux (1s) was still present in
12/23 (52%) limbs. For these, catheter-directed foam scle-
rotherapy was administered to the BK-GSV.
In group B, the BK-GSV was ablated in all cases (23/
23) compared with 19/22 (86%) in group C. The three
patent BK-GSVs in group C had persistent reflux, and these
were retreated (ultrasound guided foam sclerotherapy) at 6
weeks.
At 12 weeks, the SFJ remained competent and the
AK-GSV ablated (noncompressible shrunken vein with no
flow) in all limbs. Similarly, the BK-GSV remained oc-
cluded in all group B and C patients but two limbs in group
A showed significant below-knee reflux despite previous
foam sclerotherapy. Sequential DUS showed that following
laser ablation (AK-GSV in all groups, BK-GSV in group B),
there was a progressive, significant, reduction in vein diam-
eter. After BK-GSV sclerotherapy (groups A and C), this
had not occurred by 12 weeks. The results are summarized
in Tables III and IV.
The overall sclerotherapy requirements (to the BK-
GSV or directly into superficial varicosities) by 12 weeks
were 61% (14/23) in group A, 17% (4/23) in group B, and
36% (8/22) in group C. These difference were highly
significant (2 9.39 [2 df]), P .01 for overall data). The
difference between groups A and Bwas also significant (P
.006) but not those between B and C (P  .19), or A and
C (P  .14).
Compared with pre-EVLA, there was a significant im-
provement (P  .001) in the AVVSS score in all groups at
6 weeks (before sclerotherapy). These results are shown in
Table V. The percent improvement in AVVSS at 6 weeks
was 55.4%, 84.2%, and 72.8% for groups A, B, and C,
respectively, and this was greater in groups B and C com-
pared with group A (PA-B 0.011, PA-C 0.015). Follow-
ing foam sclerotherapy at 6 weeks, all groups showed a
further improvement in AVVSS at 12 weeks which was
greater in group A (Table V).
Median pain scores (out of 100) at 1 week were 32
(12-45), 34 (10-40), and 36 (12-50) in groups A, B, and
C, respectively, with no difference between the groups [P
.12 (A-B), 0.16 (B-C), 0.11 (A-C)]. Although some ten-
derness was recorded along the treated GSV in most limbs
CEAP)
Group B Group C
42 (27-70) 46 (31-68)
8 10
13 12
23 (21 patients) 22 (22 patients)
15 14
3 3
4 4
0 1
1 0ofat 1 week, only two patients in group C reported persistent
erothe
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nac sodium was prescribed.
Skin staining over the BK-GSV was visible at 6 weeks in
2/22 (9%) limbs in group C. No skin staining occurred
after BK-GSV EVLA. Of the 26 limbs requiring foam
sclerotherapy at 6 weeks (15 BK-GSV; 11 isolated varicos-
ities), four (15%) developed marked tenderness of the
treated vein and six (23%) skin staining.
Patient satisfaction rates at 12 weeks were 90% (A), 94%
Table III. Vein diameters (mm) of the GSV (IQR) before
measurement within the same group (1 week vs pre-EVLA
Group A
AK-GSV BK-GSV AK
Pre-EVLA 7.9 (5.9-9.2) 5.4(4.8-6.0) 7.8 (6
At 1 wk 7.4 (5.9-8.9) 5.5 (4.9-6.1) 7.6 (6
P  .46 P  .36 P 
At 6 wk 5.2 (3.6-6.4) 5.4 (4.8-6.1) 5.2 (3
P  .04 P  .32 P 
At 12 wk 3.2 (2.1-4.0) 5.3 (4.6-6.0) 3.1 (2
P  .03 P  .34 P 
EVLA, Endovenous laser ablation; GSV, great saphenous vein; IQR, interq
great saphenous vein.
Table IV. Reflux status of vein segments after EVLA (dat
delayed foam sclerotherapy)
Group A (n  23)
AK-GSV BK-GSV
At 1 wk
Ablated/occluded 23 (100%) 0
Patent, no or flash reflux 0 8 (35%)
Patent, reflux 1s 0 15 (65%)
At 6 wk
Ablated/occluded 23 (100%) 0
Patent, no or flash reflux 0 11 (48%)
Patent, reflux 1s 0 12 (52%)
At 12 wk
Ablated/occluded 23 (100%) 10 (43%)
Patent, no or flash reflux 0 11 (48%)
Patent, reflux 1s 0 2a (9%)
EVLA, Endovenous laser ablation; AK-GSV, above-knee great saphenous v
aTwo limbs in group A required further duplex ultrasound guided foam scl
Table V. Aberdeen varicose veins symptom severity scores
Pre-E
Group A 14.8 (9.
Group A (appearance of veins excluded from score)
Group B 15.8 (10
Group C 15.1 (9.
EVLA, Endovenous laser ablation.(B), and 90% (C) with no difference between the groups.Complications other than “phlebitis” were uncommon
with one patient in group C reporting transient numbness
in the distribution of saphenous nerve. There were no
instances of DVT (common or superficial femoral veins,
popliteal vein) on the DUS performed at 1 week.
DISCUSSION
Compared with standard above-knee EVLA, concom-
itant ablation (laser or sclerotherapy) of an incompetent
after EVLA: P values relate to comparison with previous
eeks vs 1 week; 12 weeks vs 6 weeks)
Group B Group C
BK-GSV AK-GSV BK-GSV
9) 5.9 (4.7-6.3) 7.7 (6.1-9.1) 5.5 (4.7-6.1)
7) 5.7 (4.6-6.2) 7.5 (6.1-9.0) 5.4 (4.5-6.1)
P  .47 P  .37 P  .32
4) 4.0 (3.1-4.8) 5.3 (3.6-6.5) 5.4 (4.3-6.0)
P  .03 P  .02 P  .49
9) 2.8 (2.1-3.3) 3.2 (2.2-4.1) 5.0 (4.0-5.9)
P  .01 P  .04 P  .09
range; AK-GSV, above-knee great saphenous vein; BK-GSV, below-knee
12 weeks represent the combined effect of EVLA and
Group B (n  23) Group C (n  22)
AK-GSV BK-GSV AK-GSV BK-GSV
23 (100%) 23 (100%) 22 (100%) 19 (86%)
0 0 0 0
0 0 0 3 (14%)
23 (100%) 23 (100%) 22 (100%) 19 (86%)
0 0 0 0
0 0 0 3 (14%)
23 (100%) 23 (100%) 22 (100%) 22 (100%)
0 0 0 0
0 0 0 0
K-GSV, below-knee great saphenous vein.
rapy at 12 weeks.
VSS) before and after EVLA
6 wk 12 wk
.6) 6.4 (3.2-9.1) 3.2 (0.5-4.9)
P (pre-6 wk) .001 P (6-12 wk) .023
5.8 (3.2-8.1) 2.9 (0.4-4.7)
P (6-12 wk) .001
4.5) 2.5 (1.1-3.7) 1.9 (0.5-2.4)
P (pre-6 wk) .001 P (6-12 wk) .073
.1) 4.1 (2.3-6.8) 2.4 (0.6-3.9)
P (pre-6 wk) .001 P (6-12 wk) .064and
; 6 w
-GSV
.0-8.
.0-8.
.38
.5-6.
.03
.2-3.
.02
uartilea for
ein; B(AV
VLA
3-22
.2-2
0-23below-knee GSV results in fewer residual varicosities and
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the requirement for delayed foam sclerotherapy. This study
also confirms that both below-knee GSV EVLA and foam
sclerotherapy are safe. Although randomization of more
patients might have resulted in significant differences in
symptom improvement (AVVSS) and sclerotherapy re-
quirements between groups B and C, this was considered
unnecessary once it became apparent that EVLA of the
BK-GSV was not associated with saphenous nerve injury.
Previous experience with EVLA indicates that some
44% of the patients require delayed foam sclerotherapy for
residual varicosities following ablation of the above-knee
GSV.6 The greater proportion (61%) of limbs requiring
sclerotherapy following standard EVLA in this study is
explained by the presence of both above and below-knee
GSV reflux in all limbs and mirrors the findings of Mona-
han10 who reported a similar rate of residual varicosities
following GSV radiofrequency ablation. Clearly, although
ablation of the above-knee GSV will abolish SFJ and prox-
imal GSV reflux, it only abolished reflux in the below-knee
GSV in half of the limbs. In the presence of persistent reflux
varicosities that connect directly to the below-knee GSV
will almost certainly remain. Conversely, ablation of both
the above and below-knee GSV should disconnect most if
not all of the varicosities from the axial vein and thus,
ablation of the GSV from midcalf to groin is more likely
control the varicose veins. In limbs where this was achieved
by EVLA, only 17% required subsequent sclerotherapy.
This study has also shown that concomitant catheter
guided below-knee GSV foam sclerotherapy following
above-knee laser ablation was also successful in abolishing
GSV reflux 19/22 (86%) and reduced the requirement for
subsequent sclerotherapy (36%), although this technique
was not as effective as full length EVLA. The failure of
chemical ablation in three patients in this group might be
explained by the use of 1% STD rather than 3% STD.
Nevertheless previous reports indicate that GSV ablation
with STD foam is unsuccessful in about 10% of pa-
tients.11-14 Although two patients in group C developed
symptomatic phlebitis, the combination of sclerotherapy
and thermal ablation is otherwise safe and more effective
than standard above-knee EVLA alone. In addition to
reducing the subsequent requirement for treating residual
varicosities, it was also accompanied by a greater improve-
ment in the AVVSS.
The frequency of skin staining following sclerotherapy
to either the BK-GSV or to residual varicosities was rela-
tively high. Although this has only been assessed at 12
weeks, and may have subsequently improved, it provides
further justification for laser ablation of both the above and
below-knee GSV when this is incompetent and technically
feasible.
Although about 85% of limbs with primary varicose
veins due to SFJ/GSV reflux are suitable for standard
above-knee EVLA,15 only 70% (67/95, Fig) with below-
knee GSV reflux were suitable for longer length EVLA
from midcalf to groin because of below-knee GSV tortuos-
ity. In these patients, concomitant above-knee EVLA andbelow-knee foam sclerotherapy would seem to offer the
most effective initial therapy.
Following above-knee EVLA persistent reflux in the
below-knee GSV was successfully treated by DUS guided
foam sclerotherapy and this explains the greater improve-
ment in AVVSS in group A between 6 and 12 weeks.
Although this might be partly explained on the basis that
these patients had more residual varicosities that were sub-
sequently ablated by foam sclerotherapy, they also had
persisting BK-GSV reflux prior to further treatment. Recal-
culation of AVVSS for group A at 6 and 12 weeks after
excluding the scores representing the extent of the residual
varicosities confirms that the improvement during this pe-
riod remained significant and thus reflects the symptomatic
benefit of abolishing BK-GSV reflux.
The impact of persistent below-knee reflux upon symp-
toms has been described previously6 and was the rationale
for designing this trial. However, we have also shown that
foam sclerotherapy directed only at the residual varicosities
did not provide additional symptom relief following suc-
cessful ablation of above-knee EVLA.16 The findings of
these studies suggest that when residual varicosities are
associated with below-knee GSV reflux following standard
EVLA further treatment should be directed at the below-
knee GSV rather than the varicosities themselves. This
would suggest that above-knee EVLA combined with mul-
tiple phlebectomies may not be as effective as some sug-
gest4 when below-knee GSV reflux is present. Further, it
requires the use of an operating theater, thus reducing the
cost-effectiveness of EVLA.
It is also clear that concomitant phlebectomy results in
the excision of some varicosities that would have resolved
spontaneously following abolition of GSV reflux particu-
larly in group B patients, only 17% of whom required
delayed sclerotherapy. Such a policy of delayed intervention
for persistent varicose veins is also promoted by Welch.5
Although the presence of residual varicosities has been
used as one of the end-points of this study, it should be
considered that following abolition of below-knee GSV
reflux, the residual varicosities are unlikely to be responsible
for symptoms. Thus, their further treatment with sclero-
therapy is only of cosmetic value. When such intervention is
offered the risk of pigmentation, the frequency which has
been reported as 0% to 67%17 must be considered.
A potential drawback to performing EVLA from mid-
calf to groin is the greater time required for the procedure.
This largely relates to the administration of the tumescent
anesthesia. Compared with the standard technique treat-
ment times for patients in groups B and C were an average
of 5 minutes longer. It might also be considered that the
risk of thermal injury to the saphenous nerve might be
greater following below-knee EVLA because of the more
intimate relationship of the nerve to the vein. We found no
evidence to suggest this.
Given that this study supports the concept that varicos-
ities that are directly connected to a refluxing axial vein will
improve after ablation of the axial vein, provided that the
point of communication is disrupted, is logical to suggest
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point below the last point of branch reflux. This will usually
require cannulation of a segment of competent axial vein
that will be of smaller diameter than the incompetent
proximal vein. Whilst more experienced clinicians may find
this relatively easy, this procedure can be facilitated by
cannulating the vein with an 18 G intravenous catheter
which is smaller than the 5 G needle supplied with the laser
fiber, but will allow insertion of the guidewire. Alterna-
tively, the vein can be hooked to the skin surface through a
small stab incision and cannulated under direct vision.
Although patients in group B had a higher satisfaction
rate compared with the other two groups, this difference
was statistically not significant. Similarly there was no dif-
ference in average pain scores during the first week indicat-
ing that the three treatment methods are equally acceptable
to patients.
In conclusion, longer length laser ablation of the great
saphenous vein from midcalf (or the lowest point of reflux)
to groin is safe and more effective than standard AK-GSV
ablation when treating patients with below-knee varicose
veins due to reflux in both the above and below-knee
segments of the GSV. Although the follow-up in this study
is short and does not provide any new data on the long-
term efficacy of EVLA, it seems logical that this technique
should be adopted whenever possible. Further, standard
EVLA can be combined with catheter guided foam sclero-
therapy to the below-knee GSV, and this method would
seem to offer the optimum therapy when tortuosity of the
below-knee GSV makes it unsuitable for EVLA.
AUTHOR CONTRIBUTIONS
Conception and design: NT, MG, AM
Analysis and interpretation: NT, MG,
Data collection: NT, DD, AM, MG
Writing the article: NT
Critical revision of the article: MG, DD, AM
Final approval of the article: NT, DD, AM, MG
Statistical analysis: NT, DD
Obtained funding: Not applicable
Overall responsibility: NT, MG
REFERENCES
1. Labropoulos N, Leon M, Nicolaides AN, Giannoukas AD, Volteas N,
Chan P. Superficial venous insufficiency: correlation of anatomic extent
of reflux with clinical symptoms and signs. J Vasc Surg 1994;20:953-8.2. Mundy L, Merlin TL, Fitridge RA, Hiller JE. Systematic review of
endovenous laser treatment for varicose veins. Br J Surg 2005;92:
1189-94 [Review].
3. Min RJ, Zimmet SE, Isaacs MN, Forrestal MD. Endovenous laser
treatment of the incompetent greater saphenous vein. J Vasc Interv
Radiol 2001;12:1167-71.
4. Mekako A, Hatfield J, Bryce J, Heng M, Lee D, McCollum P, Chetter
I. Combined endovenous laser therapy and ambulatory phlebectomy:
refinement of a new technique. Eur J Vasc Endovasc Surg 2007;32:
725-9.
5. Welch HJ. Endovenous ablation of the great saphenous vein may avert
phlebectomy for branch varicose veins. J Vasc Surg 2006;44:601-5.
6. Theivacumar NS, Dellagarammaticas D, Beale R, Mavor A, Gough M.
The clinical significance of persistent below-knee great saphenous vein
(BK-GSV) reflux following endovenous GSV laser ablation (EVLA): do
we need to modify treatment? Phlebology 2006;93:141-56.
7. TheivacumarNS, Beale RJ, Dellagrammaticas D,Mavor AI, GoughMJ.
Factors influencing the effectiveness of endovenous laser ablation
(EVLA) in the treatment of great saphenous vein reflux. Eur J Vasc
Endovasc Surg 2008;35:119-23.
8. Porter JM, Moneta GL. Reporting standards in venous disease: an
update. International Consensus Committee on Chronic Venous Dis-
ease. J Vasc Surg 1995;21:635-45.
9. Garratt AM, Macdonald LM, Ruta DA, Russell IT, Buckingham JK,
Krukowski ZH. Towards measurement of outcome for patients with
varicose veins. Qual Health Care 1993;2:5-10.
10. Monahan DL. Can phlebectomy be deferred in the treatment of vari-
cose veins? J Vasc Surg 2005;42:1145-9.
11. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new
sclerosing foam in the treatment of varicose veins. Dermatol Surg
2001;27:58-60.
12. Cabrera J, Cabrera J, Garcia-Olmedo MA. Treatment of varicose long
saphenous veins with sclerosant in microfoam: long-term outcomes.
Phlebology 2000;15:19-23.
13. Barrett JM, Allen B, Ockelford A, Goldmann MP. Microfoam ultra-
sound-guided sclerotherapy of varicose veins in 100 legs. Dermatol
Surg 2004;30:6-12.
14. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins
and telangiectases: history and analysis of safety and complications.
Dermatol Surg 2002;28:11-5.
15. Theivacumar NS, Stead L, Mavor AI, Gough MJ. Can we increase the
proportion of patients with sapheno-femoral junction (SFJ) reflux who
are suitable for endovenous laser therapy (EVLA)? Abstract presented at
Venous Forum meeting March 2007, Bristol, UK.
16. Theivacumar NS, Dellagrammaticas D, Beale R, Mavor AI, GoughMJ.
Does subsequent foam sclerotherapy provide additional symptom re-
lieve following endovenous laser therapy (EVLT) for varicose veins? Br J
Surg 2006;93(S1):147.
17. Jia X, Mowatt G, Ho V, Cook J. Systematic review of the safety and
efficacy of foam sclerotherapy for venous disease of the lower limbs.
ReBIP review body for interventional procedures; NICE Guidelines,
January 2007. (http://guidance.nice.org.uk/docref.aspx?oip244review)Submitted Oct 31, 2007; accepted Jan 31, 2008.
